Solara Q1 FY27 Net Profit Surges 55% YoY

Type of Event: Q1 FY27 Earnings Conference Call conducted after the meeting of the Board of Directors.
Date and Time: The call was conducted on Thursday, July 23, 2026. A specific time was not mentioned in the transcript.
Purpose: Discussion of financial and business highlights for the quarter ended June 30, 2026 (Q1 FY27).
Management Participants: Mr. Sandeep Rao (Managing Director and Chief Executive Officer), Mr. Sarat Kumar (Chief Financial Officer), and Mr. Abhishek Singhal (Investor Relations).
Availability of Transcript: The transcript of the call was stated to be available on the company's website within a week's time from the call date. It was subsequently filed with the exchanges on July 29, 2026.
UPSI Statement: The management indicated the discussion would be forward-looking and must be viewed in relation to business risks, but no explicit statement confirming that no Unpublished Price Sensitive Information (UPSI) would be shared was made in the provided transcript.

Consolidated Q1 FY27 Performance:

Revenue stood at INR 384 crores, up 20% Year-on-Year (YoY).
EBITDA was INR 63.5 crores, up 10% YoY.
Profit After Tax (PAT) was INR 16.3 crores, up 55% YoY.
Management noted this was the highest EBITDA and PAT achieved in the last 18 quarters.

Base Business Performance (ex-Ibuprofen):

Revenue was INR 307 crores, up 24% YoY.
Gross Margin was INR 158 crores, up 10% YoY.
EBITDA was INR 72 crores, up 8% YoY.
Gross Margin percentage for the base business was 51.3%. Management clarified that adjusting for a ~INR 17-18 crore raw material cost pass-through, the underlying gross margin profile was ~54.5%, consistent with historical ranges of 52%-55%.
The growth was attributed to geographic expansion, new business wins, and benefits from recent debottlenecking capex.
Management expressed comfort in sustaining a base business EBITDA margin of 25% ±1%.

Commodity Ibuprofen Business Performance:

The business continued to face challenges, reporting an EBITDA margin of -12%.
A marginal sequential improvement was noted, but the business is expected to continue reporting quarterly EBITDA losses in the range of INR 10-15 crores.
The strategic review for this business is ongoing and on track for a conclusion in H1 FY27 (by end of September 2026 quarter), with further details expected to be provided with the Q2 results.

Balance Sheet & Cash Flow:

Net debt reduced significantly by INR 135 crores (22% QoQ) to INR 479 crores as of June 30, 2026.
This reduction was driven by INR 100 crores from the final call money of a rights issue realized in May 2026 and INR 35 crores from operational cash flows.
The Net Debt-to-EBITDA ratio improved to 1.9x (annualizing Q1 EBITDA).
Management provided guidance to further reduce net debt to sub-INR 450 crores (around INR 440 crores) by end of March 2027, which would bring the ratio down to ~1.7x.

Operational Priorities & Outlook:

Management outlined three key priorities: 1) Expanding existing business and seeding new businesses, 2) Driving operational efficiency and debottlenecking to maximize output, and 3) Working capital optimization to generate free cash flow.
For FY27, the company has committed a capex of INR 55-60 crores, predominantly (INR 40 cr) for high-return debottlenecking projects with expected paybacks within 2-3 quarters, and the remainder for maintenance.
A sustainable year-on-year revenue growth rate of at least 10% for the base business is anticipated.

Macro Challenges:

The ongoing West Asia crisis was cited as a significant headwind, causing raw material (solvent) price inflation and supply chain disruptions.
The company estimated a revenue impact of ~INR 30 crores from passing through these higher costs to customers. Transparency with customers helped in securing acceptance for most of these price increases.
The new tariff schemes announced by the U.S. President were mentioned, but management awaits clarity on the implementing framework and product scope (APIs vs. formulations) before assessing any potential impact.

The document provided was the full transcript of the earnings conference call, filed as an enclosure with the stock exchanges.
No new financial data beyond the announced quarterly results was disclosed in this transcript; it contained management commentary and Q&A based on the published results.
The transcript included detailed Q&A with analysts and investors covering topics like growth sustainability, margin drivers, capacity utilization (~70% across base business sites), Ibuprofen strategy, and capital allocation.